 LA JOLLA, Calif., March 15, 2021 PRNewswire -- Avidity Biosciences, Inc. Nasdaq: RNA, a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates AOCsTM, today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress. 